Heart disease helped by A2-73? Below copied from IHUB’s falconer66a,
Fletch
http://patentscope.wipo.int/search/de/detail....ec=2082820
falconer66a Friday, 04/26/19 12:02:32 PM
Re: TTTav66 post# 190499 0
Post # of 190511
So, Now, Heart Disease
Quote:
New Patent Title: Anavex 2-73 or Anavex 19-144 (2-73's active metabolite) for the Treatment of Cardiac Dysfunction
Noting the profound downstream outcomes of Anavex-facilitated protein folding in the endoplasmic reticulum, whereby proper, fully-functioning enzyme proteins are created, I’ve previously claimed that effective therapeutic applications of Anavex 2-73 will not be limited to Rett syndrome, Parkinson’s disease, nor Alzheimer’s. Those three central nervous system diseases are currently in human clinical trials, but because of the broad-based mechanism of action of the molecule, there will certainly be other therapeutic applications.
Mis-folded proteins, resulting from mitochondrial dysfunction — corrected by Anavex 2-73 — are involved in, or a direct cause of a host of diseases, both in the central nervous system and elsewhere. Here, Anavex Life Sciences Corp (or its agent) files for a patent claiming that a metabolite of Anavex 2-73 is therapeutic for cardiac dysfunction.
Great. But pretty much as I expected. I’ve claimed for some time that Dr. Missling’s people a) know in detail the various biochemistries of the company’s sigma-1 receptor agonists, and because of this b) they can apply the drug to a host of otherwise unconnected diseases and conditions; the pathologies of which are caused by mis-folded proteins, non-functioning enzymes.
Quick Biology 101 review. Nucleotide sequences (A’s, T’s, G’s, C’s) in DNA code for the sequencing of specific amino acids, making peptides; short protein fragments.
Then, in the endoplasmic reticulum the peptides are sequenced into full-sized proteins, which, finally are precisely folded into working enzymes. Those diffuse through the cell and control and moderate virtually all chemical reactions in the cell.
But if the proteins composing enzymes are mis-folded, which happens when the chemistries of the sigma-1 receptors are malfunctioning, a host of diseases result — not just the three CNS diseases being test.
In the next two or three years, let’s see what new diseases and health conditions Anavex Life Sciences Corp will be targeting with their proprietary (patented) molecules. Won’t be just three CNS diseases. What will the results be if the company can also treat heart diseases of some sort?
https://investorshub.advfn.com/boards/read_ms...=148459939
Fletch
http://patentscope.wipo.int/search/de/detail....ec=2082820
falconer66a Friday, 04/26/19 12:02:32 PM
Re: TTTav66 post# 190499 0
Post # of 190511
So, Now, Heart Disease
Quote:
New Patent Title: Anavex 2-73 or Anavex 19-144 (2-73's active metabolite) for the Treatment of Cardiac Dysfunction
Noting the profound downstream outcomes of Anavex-facilitated protein folding in the endoplasmic reticulum, whereby proper, fully-functioning enzyme proteins are created, I’ve previously claimed that effective therapeutic applications of Anavex 2-73 will not be limited to Rett syndrome, Parkinson’s disease, nor Alzheimer’s. Those three central nervous system diseases are currently in human clinical trials, but because of the broad-based mechanism of action of the molecule, there will certainly be other therapeutic applications.
Mis-folded proteins, resulting from mitochondrial dysfunction — corrected by Anavex 2-73 — are involved in, or a direct cause of a host of diseases, both in the central nervous system and elsewhere. Here, Anavex Life Sciences Corp (or its agent) files for a patent claiming that a metabolite of Anavex 2-73 is therapeutic for cardiac dysfunction.
Great. But pretty much as I expected. I’ve claimed for some time that Dr. Missling’s people a) know in detail the various biochemistries of the company’s sigma-1 receptor agonists, and because of this b) they can apply the drug to a host of otherwise unconnected diseases and conditions; the pathologies of which are caused by mis-folded proteins, non-functioning enzymes.
Quick Biology 101 review. Nucleotide sequences (A’s, T’s, G’s, C’s) in DNA code for the sequencing of specific amino acids, making peptides; short protein fragments.
Then, in the endoplasmic reticulum the peptides are sequenced into full-sized proteins, which, finally are precisely folded into working enzymes. Those diffuse through the cell and control and moderate virtually all chemical reactions in the cell.
But if the proteins composing enzymes are mis-folded, which happens when the chemistries of the sigma-1 receptors are malfunctioning, a host of diseases result — not just the three CNS diseases being test.
In the next two or three years, let’s see what new diseases and health conditions Anavex Life Sciences Corp will be targeting with their proprietary (patented) molecules. Won’t be just three CNS diseases. What will the results be if the company can also treat heart diseases of some sort?
https://investorshub.advfn.com/boards/read_ms...=148459939
2
